BR0116151A - Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica - Google Patents

Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica

Info

Publication number
BR0116151A
BR0116151A BR0116151-2A BR0116151A BR0116151A BR 0116151 A BR0116151 A BR 0116151A BR 0116151 A BR0116151 A BR 0116151A BR 0116151 A BR0116151 A BR 0116151A
Authority
BR
Brazil
Prior art keywords
induced
factor vii
bleeds
coagulation factor
activated coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0116151-2A
Other languages
English (en)
Inventor
Cord Skamira
Jean Marie Stassen
Gerhard Heusel
Wolfgang Wienen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BR0116151A publication Critical patent/BR0116151A/pt
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"USO DE FATOR DE COAGULAçãO ATIVADA VII PARA TRATAMENTO DE SANGRAMENTOS PRINCIPAIS INDUZIDOS NA TERAPIA TROMBOLìTICA". A invenção refere-se a grandes sangramentos induzidos por terapia trombolítica/fibrinolítica, incluindo hemorragias intracraniais que são tratadas, administrando ao indivíduo sofrendo de tais sangramentos, uma quantidade eficaz de fator VII (VIIa) ativado de coagulação ou um derivado funcional do mesmo.
BR0116151-2A 2000-12-21 2001-12-20 Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica Pending BR0116151A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128252A EP1216709A1 (en) 2000-12-21 2000-12-21 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings
PCT/EP2001/015132 WO2002049665A2 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Publications (1)

Publication Number Publication Date
BR0116151A true BR0116151A (pt) 2003-10-21

Family

ID=8170769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116151-2A Pending BR0116151A (pt) 2000-12-21 2001-12-20 Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica

Country Status (25)

Country Link
US (2) US20040087502A1 (pt)
EP (2) EP1216709A1 (pt)
JP (1) JP2004516273A (pt)
KR (1) KR20030063454A (pt)
CN (1) CN1482919A (pt)
AT (1) ATE353666T1 (pt)
AU (2) AU2638602A (pt)
BR (1) BR0116151A (pt)
CA (1) CA2431986A1 (pt)
CY (1) CY1106363T1 (pt)
CZ (1) CZ300670B6 (pt)
DE (1) DE60126650T2 (pt)
DK (1) DK1343523T3 (pt)
EC (1) ECSP034647A (pt)
ES (1) ES2280429T3 (pt)
HU (1) HUP0302574A3 (pt)
IL (1) IL155886A0 (pt)
MX (1) MXPA03005641A (pt)
NZ (1) NZ549850A (pt)
PL (1) PL205878B1 (pt)
PT (1) PT1343523E (pt)
RU (1) RU2286796C2 (pt)
SI (1) SI1343523T1 (pt)
WO (1) WO2002049665A2 (pt)
ZA (1) ZA200304140B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761274B1 (en) * 2004-06-21 2009-09-02 Novo Nordisk Health Care AG Factor viia or factor viia equivalents for preventing or attentuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
EP1906993A2 (en) * 2005-07-15 2008-04-09 Novo Nordisk Health Care AG USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY
US8354377B2 (en) 2008-01-18 2013-01-15 Novo Nordisk Health Care Ag Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
RU2552339C1 (ru) * 2014-02-19 2015-06-10 Общество с ограниченной ответственностью фирма "Технология-Стандарт" Способ профилактики кровотечений, вызванных применением стрептокиназы, в эксперименте

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

Also Published As

Publication number Publication date
DE60126650T2 (de) 2007-10-31
WO2002049665A3 (en) 2002-09-26
SI1343523T1 (sl) 2007-04-30
CZ20031743A3 (cs) 2003-11-12
PL361855A1 (en) 2004-10-04
EP1343523A2 (en) 2003-09-17
KR20030063454A (ko) 2003-07-28
RU2286796C2 (ru) 2006-11-10
CY1106363T1 (el) 2011-10-12
CA2431986A1 (en) 2002-06-27
EP1343523B1 (en) 2007-02-14
AU2002226386B2 (en) 2005-12-22
ES2280429T3 (es) 2007-09-16
DK1343523T3 (da) 2007-04-10
PT1343523E (pt) 2007-03-30
US20080286259A1 (en) 2008-11-20
CN1482919A (zh) 2004-03-17
HUP0302574A3 (en) 2010-01-28
ATE353666T1 (de) 2007-03-15
JP2004516273A (ja) 2004-06-03
DE60126650D1 (de) 2007-03-29
US20040087502A1 (en) 2004-05-06
PL205878B1 (pl) 2010-06-30
WO2002049665A2 (en) 2002-06-27
IL155886A0 (en) 2003-12-23
EP1216709A1 (en) 2002-06-26
ECSP034647A (es) 2003-07-25
AU2638602A (en) 2002-07-01
CZ300670B6 (cs) 2009-07-15
HUP0302574A2 (hu) 2003-10-28
ZA200304140B (en) 2004-04-22
NZ549850A (en) 2008-04-30
MXPA03005641A (es) 2004-12-03
RU2003122362A (ru) 2005-02-10

Similar Documents

Publication Publication Date Title
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
DE60035870D1 (de) Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
ATE227306T1 (de) Thrombin-inhibitoren als anticoagulierende mittel
BR0316502A (pt) Compostos quìmicos
UY26130A1 (es) Compuestos para tratar la obesidad
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0117009A (pt) Composiçoes para utilização no tratamento de distúrbios associados a ige
BRPI0410663A (pt) compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]